Phenylalanine-tRNA aminoacylation is compromised by ALS/FTD-associated C9orf72 C4G2 repeat RNA

Reagents

The following primary antibodies and dilutions were used: FARSA (18121-1-AP; WB 1:1000; IF/PLA 1:500), FARSB (16341-1-AP; WB 1:1000; IF/PLA 1:500), TAOK1 (23379-1-AP; WB 1:1000, IF/PLA 1:500), CNP (13427-1-AP; WB 1:1000), CYFIP1/2 (16011-1-AP; WB 1:1000), GAPDH (60004-1-Ig, lot: 10013030 and 10494-1-AP; WB 1:5000), TSPAN5 (12122-1-AP; WB 1:500), PXMP2 (24801-1-AP; WB 1:600), LARS (21146-1-AP; WB 1:500, PLA 1:100), NARS (14882-1-AP; WB 1:500, PLA 1:100), EPRS (25307-1-AP; WB 1:500, PLA 1:100), HA (66006-2-ig, lot: 10011878; WB, 1:1000) (all from Proteintech, Rosemont, Illinois, USA); HNRNPL (sc-32317, lot: 4D11; WB 1:500, IF 1:100), HNRNPK (sc-28380, lot: D-6; WB 1:500, IF 1:100), NPM1 (sc-56622; WB 1:100), Lamin B1 (sc20682, lot: H90; WB 1:5000), Syp/Synaptophysin (sc-17750, lot: D0419; WB 1:1000) (all from Santa Cruz Biotechnology, Dallas, Texas, USA); Histone H3 (NB500-171; WB 1:1000), ALG10B (NBP3-09560; WB…

Read more…